TALPHERA, INC. (TLPH): auditor change — AcelRx restates interim 2022 financials due to EPS error; divests DSUVIA to Alora for royalties and milestones

TALPHERA, INC.

Non-reliance on Q2 and Q3 2022 financials due to EPS calculation error (two-class method for warrants); no impact on cash, revenue, or net income.
Divests DSUVIA to Alora Pharmaceuticals; receives 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.
Cash and short-term investments $20.8M as of Dec 31, 2022; Q4 2022 net loss $7.5M ($1.00 per share) vs $7.9M ($1.24) in Q4 2021.
Full-year 2022 DSUVIA net sales $1.8M, up 76% YoY; combined R&D and SG&A expenses $7.3M in Q4 2022.
Niyad (nafamostat) EUA submission planned for Q2 2023; Fedsyra NDA submission by end of Q2 2023.

item 2.02 item 4.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

TALPHERA, INC. reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

On March 30, 2023, the Company's management and the Audit Committee of the Company determined that the Company's Prior Period Financial Statements for the Interim Periods, should no longer be relied upon because of the error in the earnings per share calculations.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TALPHERA, INC. reported financial results for full year and fourth quarter 2022.

Period: full year and fourth quarter 2022
Result: reported results

Exact text from the filing

AcelRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022 and providing a corporate update (the “Release”).

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-008621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.